Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1234.60
-10.90 (-0.88%)
< Home < Back

Dr. Reddy's Laboratories launches Icosapent Ethyl Capsules

Date: 22-06-2021

Dr. Reddy’s Laboratories has launched Icosapent Ethyl Capsules, 1 gram approved by the U.S. Food and Drug Administration (USFDA). The company’s Icosapent Ethyl Capsules, 1 gram is approved for the following indication: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

The company’s Icosapent Ethyl is available in 1 gram capsules in bottle count size of 120’s count. The effect of Icosapent Ethyl Capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.